Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pregabalin for uraemic pruritus in conservatively managed advanced kidney disease
ACTRN12621001626853Phase 2Completed
- Sponsor
- University of Technology Sydney
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pregabalin in chronic kidney disease-associated pruritus (CKD-aP), sponsored by University of Technology Sydney. Primary endpoint: Feasibility of recruitment and retention. Started Oct 2023; status: completed.
02
Drugs
pregabalin
03
Conditions
chronic kidney disease-associated pruritus (CKD-aP)
Beyond the preview
Go deeper on ACTRN12621001626853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001626853.